Oncology Results Can Be Clearer If Trials Target Early Stages – FDA’s Pazdur

Oncology drug developers should conduct randomized trials in less heavily pre-treated patients to gain a clearer picture of the drug's efficacy, FDA Oncology Division Director Richard Pazdur said